KRAS / RAS targeting: from platform to Phase 3
Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).
Encouraging results from #AACR26 on Elisrasib (D3S-001) for KRAS G12C NSCLC by Dr. Cho
Key highlights:
2L+ G12Ci Naïve: 59.5% ORR, mDOR 14.9 months.
3L+ G12Ci Refractory: 32.3% PR rate, mDOR 15.6 months.
Mechanism: CNS penetrable; overcomes resistance in
Heat 14 · 10 likes · 1 reply · 3 reposts
Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Read the abstract →Source: Young Kwang Chae, MD, MPH, MBA · x.com